Lymphoseek bests standard dye, researchers find

03/25/2013 | News-Medical.Net

The recently approved radioactive agent Lymphoseek, technetium Tc-99m tilmanocept, was able to detect cancerous lymph nodes and performed better than the standard agent in identifying cancers, according to findings published in the Annals of Surgical Oncology. Researchers found that more than 99% of sentinel lymph nodes with standard dye uptake also had Lymphoseek. Lymphoseek identified 94% of malignancies, compared with 76% for the standard blue dye. "This could standardize the process of lymph node mapping and make the process easier, particularly for less experienced surgeons," said principal investigator Dr. Anne Wallace from the University of California, San Diego.

View Full Article in:

News-Medical.Net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC